nrf2 inhibitor (MedChemExpress)
Structured Review

Nrf2 Inhibitor, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 97/100, based on 738 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nrf2 inhibitor/product/MedChemExpress
Average 97 stars, based on 738 article reviews
Images
1) Product Images from "Metformin alleviates aging-associated periodontitis via NRF2-mediated restoration of the IRE1α dependent unfolded protein response"
Article Title: Metformin alleviates aging-associated periodontitis via NRF2-mediated restoration of the IRE1α dependent unfolded protein response
Journal: Bioactive Materials
doi: 10.1016/j.bioactmat.2026.03.060
Figure Legend Snippet: SASP and NRF2 expression in periodontal tissues from young and aged individuals with or without periodontitis. Periodontal tissues and PDLSCs were collected from young (≤25 years), middle-aged (35-45 years), and aged (≥60 years) individuals, with or without periodontitis. (A) Schematic diagram of the experimental procedure. (B, C) SA-β-gal (B) and P21 (C) staining in periodontal tissues of young (Young), young individuals with periodontitis (Young + PD), aged individuals (Aged), and aged individuals with periodontitis (Aged + PD). (D) RT-qPCR analysis of mRNA expression levels of IL1β , TNFα , IL6 , IL8 , MMP3 , and MMP13 in periodontal tissues. (E) IF staining for NFR2 in periodontal tissues. (F) Western blot analysis of NRF2 expression in PDLSCs collected from young (Young), middle-aged (Middle), and aged (Aged) individuals. (G) NRF2 expression levels in PDLSCs at different passages (Passage 3, 9, and 12) with or without LPS (10 μg/ml) treatment. ns, not significant; PD, periodontitis; IF, Immunofluorescence. Data are presented as means ± SEM, with n = 3-5 for each subgroup. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001.
Techniques Used: Expressing, Staining, Quantitative RT-PCR, Western Blot, Immunofluorescence
Figure Legend Snippet: Overexpression of Nrf2 suppresses SASP in senescent PDLSCs. PDLSCs were transduced with adenovirus carrying Nrf2 (Adv- NRF2 ) or control virus (Adv- GFP ), followed by treatment with LPS (10 μg/ml) with or without D-gal (30 mg/ml). (A) Representative images of SA-β-gal staining, followed by quantification. (B) Western blot analysis of P16 and P21 protein levels. (C) mRNA expression levels of IL1β , TNFα , IL6 , IL8 , TNFα , MMP3 , and MMP13 in PDLSCs. (D, E) ALP (D) and ARS (E) staining of PDLSCs. (F) Western blot analysis and quantification of COL-1α1, RUNX2, OPN, and ALP protein expression levels in PDLSCs after 7 days of osteogenic induction. ns, not significant. Data are presented as means ± SEM (n = 3 per subgroup). ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001.
Techniques Used: Over Expression, Transduction, Control, Virus, Staining, Western Blot, Expressing
Figure Legend Snippet: Nrf2 knockout aggravates SASP and alveolar bone resorption. (A) Schematic diagram of the experimental procedure. (B, C) IF staining of SA-β-gal (B) and P21 (C) in periodontal tissues from WT and Nrf2 −/− mice, settled with a periodontitis model and D-gal induced aged mouse model. (D) Relative mRNA level of Il1β in mice periodontal tissue. (E) Micro-CT reconstructions, followed by 3D and 2D views of maxillary molars and evaluation of the distance from the CEJ to the ABC. (F, G) Mice periodontal tissue sections prepared for H&E staining (F) and Masson's trichrome staining (G). ns, not significant. Data are presented as means ± SEM (n = 5 per subgroup). ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001.
Techniques Used: Knock-Out, Staining, Micro-CT
Figure Legend Snippet: NRF2 restores UPR function through upregulating IRE1α. (A, B) PDLSCs were transduced with an adenovirus vector or loaded with NRF2 (Adv- GFP / NRF2 ), followed by administrated with LPS and/or D-gal. Western blot for UPR markers (A) in PDLSCs. IF staining for IRE1α in PDLSCs (B). (C, D) PDLSCs were administered with NRF2 inhibitor (ML385), followed by treatment with LPS and/or D-gal. Protein levels of UPR markers (C). IF staining for IRE1α (D). (E) IF staining of IRE1α in WT and Nrf2 −/− mice, settled with the periodontitis model and D-gal induced aged mouse model. (F) Prediction of NRF2's binding motifs on the promoters of UPR markers in the JASPAR database ( https://jaspar.elixir.no/ ). (G) Prediction of the relationship between NRF2 and IRE1α mRNA expression in the GEPIA database ( http://gepia.cancer-pku.cn/ ). (H) CUT-RUN-qPCR assay and agarose gel electrophoresis for the binding of NRF2 to IRE1α promoter in PDLSCs. Data are presented as means ± SEM (n = 3 per subgroup). ∗P < 0.05.
Techniques Used: Transduction, Plasmid Preparation, Western Blot, Staining, Binding Assay, Expressing, Agarose Gel Electrophoresis
Figure Legend Snippet: Metformin suppresses SASP and upregulates NRF2 and UPR markers expression in senescent PDLSCs. (A) P16 and P21 expression in PDLSCs treated with metformin combined with LPS and D-gal. (B) SA-β-gal staining of PDLSCs. (C) mRNA expression level in PDLSCs. (D) Western blot for NRF2 and UPR markers in PDLSCs treated with metformin combined with LPS and D-gal. (E, F) IF staining for IRE1α (E) and NRF2 (F) in PDLSCs. (G, H) ALP (G) and ARS (H) staining of PDLSCs followed by osteogenic induction for 7 and 21 days, respectively. (I) Protein expression levels of osteogenic markers in PDLSCs were followed by 7 days of osteogenic induction. Data are presented as means ± SEM (n = 3 per subgroup). ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001.
Techniques Used: Expressing, Staining, Western Blot
Figure Legend Snippet: Metformin suppresses SASP and UPR via NRF2. (A) Schematic diagram of the experimental procedure. PDLSCs were pretreated with D-gal and LPS, followed by administration with metformin and/or NRF2 inhibitor (ML385). (B) Representative images of SA-β-gal staining for PDLSCs. (C) Protein expression level of P21 and P16. (D) Relative mRNA expression of IL1β , IL6 , IL8 , TNFα , MMP3 , and MMP13 in PDLSCs. (E) Western blot analysis of UPR markers expression levels in PDLSCs. (F) Transmission electron microscopy (TEM) images of ER morphology in PDLSCs. ns, not significant. Data are presented as means ± SEM (n = 3 per subgroup). ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001.
Techniques Used: Staining, Expressing, Western Blot, Transmission Assay, Electron Microscopy
Figure Legend Snippet: TAM-GM@Met suppresses SASP and upregulates NRF2 and UPR markers expression in senescent PDLSCs. (A) Schematic diagram of the co-culture of hydrogels with PDLSCs. (B) Western blot for P16 and P21 protein expression in PDLSCs treated with composite hydrogels combined with LPS and D-gal pre-treated with D-gal and LPS. (C) SA-β-gal staining of PDLSCs. (D) SASP mRNA expression level in PDLSCs. (E, F) ALP (E) and ARS (F) staining of PDLSCs followed by osteogenic induction for 7 and 21 days, respectively. (G) Protein expression levels of osteogenic markers in PDLSCs followed by 7 days of osteogenic induction. (H) Western blot for NRF2 and UPR markers in PDLSCs treated with metformin combined with LPS and D-gal. ns, not significant. Data are presented as means ± SEM (n = 3 per subgroup). ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001.
Techniques Used: Expressing, Co-Culture Assay, Western Blot, Staining
Figure Legend Snippet: In vivo therapeutic effect of the TAM-GM@Met on mice with an aging-associated periodontitis model. (A) Schematic illustration of the therapeutic process on the D-gal induced aging mice periodontitis model. (B) Micro-CT reconstructions and buccal-palatal sectional views of maxillary molars and evaluation of the distance from the CEJ to the ABC. (C, D) Mice periodontal tissue sections prepared for H&E staining (C) and Masson's trichrome staining (D). (E) Schematic of TAM-GM@Met preparation. TAM hydrogel incorporates galactose-coated MPDA nanoparticles (GM) to target senescent cells for metformin delivery. Metformin activates NRF2, leading to transcriptional upregulation of IRE1α, restoration of the UPR, and suppression of SASP in PDLSCs. ns, not significant; TAM, tannic acid and Ag-MOFs based hydrogel; MPDA, mesoporous polydopamine; UPR, unfolded protein response. Data are presented as means ± SEM (n = 5 per subgroup). ∗∗∗P < 0.001.
Techniques Used: In Vivo, Micro-CT, Staining

